- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04783545
Phase I Study of VLX-1005 in Healthy Subjects
A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous VLX-1005 in Healthy Subjects
The principal objective of this study is to describe the safety of and tolerability to single and multiple doses of VLX-1005 in healthy subjects following intravenous (IV) administration.
Other exploratory objectives are:
To evaluate the pharmacokinetics and pharmacodynamics of VLX-1005 following IV administration.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy, adult, male or female (non-lactating and not of childbearing potential) subjects age 19 to 55 inclusive.
Females must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:
- hysteroscopic sterilization
- bilateral tubal ligation or bilateral salpingectomy
- hysterectomy
- bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle stimulating hormone (FSH) serum levels consistent with postmenopausal status.
- Good general health, with no significant medical history. Subjects must have no clinically significant abnormalities on physical examination at screening, and/or before administration of the initial dose of study drug.
- Body weight ≥ 50 kg at the screening visit.
- Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive.
- Has laboratory values (clinical chemistry and hematology) within the normal reference range. Deviations from this range may be acceptable if they are considered 'not clinically significant' (NCS) by the PI.
- Males who have not been vasectomized participating in the study must agree to use at least 2 approved methods of contraception (ie double-barrier or barrier plus hormonal), or abstain from sexual intercourse, from Day -2 to 4 weeks after dosing (or last dose Parts B)
- Is a non-smoker and must not have used any nicotine products within three months prior to screening.
- Able and willing to attend the necessary visits to the study center.
Exclusion Criteria:
- Blood donation or recipient of blood transfusion in previous 12 weeks.
- History of clinically significant endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases. Cardiovascular history should include assessment of risk factors for Torsades de Pointes Risk (e.g., heart failure, pulmonary edema, cardiomyopathy, hypokalemia, hypomagnesemia, or hypocalcemia, or family history of Long QT Syndrome, syncope or sudden death).
- History of neoplastic disease (with the exception of adequately treated non-melanomatous skin carcinoma).
- Mentally or legally incapacitated (e.g., has significant emotional problems at the time of Screening Visit or expected during the conduct of the study, or has a history of a clinically significant psychiatric disorder within the last 5 years).
- Fever (body temperature >38C) or symptomatic viral/bacterial infection or use of antibi-otics within 2 weeks prior to Screening.
- Supine resting blood pressure (BP) >140/90 mmHg or heart rate (HR) outside the range 40 to 100 beats per minute at Screening and at Day -1.
- Clinically significant abnormality on ECG performed at the Screening Visit or prior to administration of the initial dose of study drug. (Sick sinus syndrome, second or third degree atrioventricular block, myocardial infarction, symptomatic or significant cardiac arrhythmia, prolonged QTcF interval, or bundle branch block.
- Out of range (on repeat) testing for coagulation tests including fibrinogen.
- Clinically significant laboratory abnormalities including: Impaired renal function (estimated creatinine clearance (CrCl) of <80 mL/minute based on CrCl = (140-age [years])(body weight [kg])/(72)(serum creatinine [mg/dL])).
- Positive test for hepatitis C antibody, hepatitis B surface antigen, or human immunodefi-ciency virus (HIV) antibody at Screening.
- Participants with a positive toxicology screening panel (urine test including qualitative identi¬fication of barbiturates, tetrahydrocannabinol, amphetamines, benzodiazepines, opiates, cocaine, cotinine and ethanol).
- Participants with a history of substance abuse or dependency or history of recreational IV drug use (by self-declaration).
- Participant has a suspected history of alcohol abuse in the 6 months prior to screening.
- Use of NSAIDs, aspirin or aspirin-containing medications (and other medications affecting platelet function [for example cilostazol, clopidogrel, ticagrelor, prasugrel, dipyridamole]) in the 14 days prior to dosing with study medication.
- Unable to refrain from or anticipates the use of any medications, including prescription and non-prescription drugs and herbal remedies (such as St. John's Wort [Hypericum perforatum]), beginning 14 days (or 5 half-lives, whichever is longer) before administration of the initial dose of study drug and continuing throughout the study until the final study visit. There may be certain medications that are permitted at the discretion of the Investigator and Sponsor (including paracetamol/acetaminophen, medications for the treatment of AEs following administration of study drug).
- Subjects who are unlikely to comply with the study protocol or, in the opinion of the investigator, would not be a suitable candidate for participation in the study.
- Have participated in any other investigational drug trial within 30 days of dosing in the present study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Ascending Dose Cohorts 1-6
Drug: VLX-1005
|
VLX-1005 infusion
|
Placebo Comparator: Single Ascending Dose Cohorts 1-6, Placebo
Drug: Placebo
|
Placebo infusion
|
Experimental: Multiple Ascending Dose Cohorts 7-9
Drug: VLX-1005
|
VLX-1005 infusion
|
Placebo Comparator: Multiple Ascending Dose Cohorts 7-9, Placebo
Drug: Placebo
|
Placebo infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Reporting One or More Treatment-emergent Adverse Events
Time Frame: Baseline up to Day 29
|
Baseline up to Day 29
|
Number of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose
Time Frame: Baseline up to Day 29
|
Baseline up to Day 29
|
Number of Participants Who Meet the Markedly Abnormal Criteria for 12-lead Electrocardiogram (ECG) or Telemetry Parameters at Least Once Post Dose
Time Frame: Baseline up to Day 29
|
Baseline up to Day 29
|
Number of Participants Who Meet the Markedly Abnormal Criteria for Laboratory Values at Least Once Post Dose
Time Frame: Baseline up to Day 29
|
Baseline up to Day 29
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC(inf)
Time Frame: day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion
|
Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for VLX-1005
|
day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion
|
C(max)
Time Frame: day 1 at the end of infusion (1 hour after infusion starts)
|
Plasma Concentration at the end of Infusion for VLX-1005
|
day 1 at the end of infusion (1 hour after infusion starts)
|
T1/2
Time Frame: day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion
|
Terminal Disposition Phase Half-life for VLX-1005
|
day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion
|
Pharmacodynamics of 12-Lipoxygenase Inhibition
Time Frame: day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion
|
12-HETE measurement in serum
|
day 1 pre-infusion and at multiple time points (up to 36 hours) post infusion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Allen Hunt, MD, Celerion
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- VLX-1005-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety and Tolerability in Healthy Volunteers
-
Annexon, Inc.TerminatedSafety and Tolerability in Healthy VolunteersAustralia
-
Neuraly, Inc.CompletedSafety and Tolerability in Healthy VolunteersUnited States
-
Annexon, Inc.Nucleus Network LtdCompletedSafety and Tolerability in Healthy VolunteersAustralia
-
Astellas Pharma Global Development, Inc.Basilea Pharmaceutica International LtdCompletedHealthy Volunteers | Pharmacokinetics of Isavuconazole | Safety and Tolerability in ElderlyUnited States
-
LG ChemCompletedBioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy VolunteersKorea, Republic of
-
ARC Medical Devices Inc.Completed
-
BioGaia ABCompletedHealthy Volunteers | Tolerability | SafetySweden
-
Bioniz TherapeuticsCelerionCompletedSafety and Tolerability in Healthy SubjectsUnited States
-
TheracosCompletedSafety and Tolerability of EGT0001474 in Healthy VolunteersUnited States
-
Xencor, Inc.ICON Clinical ResearchCompletedSafety in Healthy VolunteersUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States